Sunday, November 15, 2026 Vol. I · No. 3
World · Via South China Morning Post

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Image: South China Morning Post

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative…

This is a brief. The reporting belongs to South China Morning Post — read the complete story, with full context and credits, at the source.

Read the full story at South China Morning Post ↗

scmp.com

More from the World desk